Replimune Group (NASDAQ:REPL) Stock Price Up 6.4% – What’s Next?

Replimune Group, Inc. (NASDAQ:REPL) traded up 6.4% during trading on Wednesday . The company traded as high as $8.76 and last traded at $8.94. 291,629 shares changed hands during mid-day trading, a decline of 66% from the average session volume of 858,083 shares. The stock had previously closed at $8.40.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on REPL shares. JPMorgan Chase & Co. upped their target price on Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. BMO Capital Markets raised their target price on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Jefferies Financial Group upped their price target on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Finally, HC Wainwright increased their price target on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $19.43.

Replimune Group Trading Up 7.3 %

The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The firm has a fifty day simple moving average of $12.60 and a two-hundred day simple moving average of $12.14. The firm has a market capitalization of $693.91 million, a P/E ratio of -2.93 and a beta of 1.30.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). On average, equities research analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Institutional Trading of Replimune Group

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Sterling Capital Management LLC raised its position in shares of Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after buying an additional 1,655 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Replimune Group by 696.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock worth $82,000 after acquiring an additional 5,922 shares in the last quarter. Aster Capital Management DIFC Ltd increased its stake in Replimune Group by 8,798.9% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after acquiring an additional 8,183 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Replimune Group during the fourth quarter valued at about $117,000. Finally, Quantinno Capital Management LP purchased a new stake in Replimune Group during the fourth quarter valued at about $127,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.